Login to Your Account



Takeda Snags Orexigen's Obesity Drug in $1B-Plus Deal

By Catherine Hollingsworth


Friday, September 3, 2010
Another Japanese firm has partnered for an obesity compound that is under review by the FDA. This time, Takeda Pharmaceutical Co. Ltd. has agreed to pay at least $1.05 billion to market Orexigen Therapeutics Inc.'s Contrave in North America. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription